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Background: Different studies have described the successful use of recombinant lactic acid bacteria (recLAB) to
deliver anti-inflammatory molecules at the mucosal level to treat Inflammatory Bowel Disease (IBD).
Methods: In order to identify the best strategy to treat IBD using recLAB, we compared the efficacy of different
recombinant strains of Lactococcus lactis (the model LAB) secreting two types of anti-inflammatory molecules:
cytokines (IL-10 and TGF-β1) and serine protease inhibitors (Elafin and Secretory Leukocyte Protease Inhibitor: SLPI),
using a dextran sulfate sodium (DSS)-induced mouse model of colitis.
Results: Our results show that oral administration of recombinant L. lactis strains expressing either IL-10 or TGF-β1
display moderate anti-inflammatory effects in inflamed mice and only for some clinical parameters. In contrast, delivery
of either serine protease inhibitors Elafin or SLPI by recLAB led to a significant reduction of intestinal inflammation for
all clinical parameters tested. Since the best results were obtained with Elafin-producing L. lactis strain, we then tried to
enhance Elafin expression and hence its delivery rate by producing it in a L. lactis mutant strain inactivated in its major
housekeeping protease, HtrA. Strikingly, a higher reduction of intestinal inflammation in DSS-treated mice was observed
with the Elafin-overproducing htrA strain suggesting a dose-dependent Elafin effect.
Conclusions: Altogether, these results strongly suggest that serine protease inhibitors are the most efficient
anti-inflammatory molecules to be delivered by recLAB at the mucosal level for IBD treatment.
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Inflammatory bowel disease (IBD) is a group of chronic
inflammatory disorders that cause inflammation of the
digestive tract. The two major forms of IBD are Crohn’s
Disease (CD) and Ulcerative Colitis (UC) and they are
characterized by an uncontrolled inflammatory response
to lumenal content [1]. Despite the fact that several anti-
inflammatory molecules have been tested in preclinical
and clinical models for IBD treatment, their therapeutic* Correspondence: philippe.langella@jouy.inra.fr
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article, unless otherwise stated.potential and clinical application have been frequently
hampered by different obstacles such as successful deliv-
ery or even toxic side-effects [1]. In the last 10 years, an
increasing number of clinical and experimental studies
have proven that probiotic bacteria may counteract the
chronic inflammatory process. This effect is achieved by
stabilizing the gut microbial environment and perme-
ability barrier functions and by modulating the micro-
biota composition [2,3]. In addition, the successful use
of food-grade Lactic Acid Bacteria (LAB) for the oral de-
livery of anti-inflammatory molecules to the inflamed in-
testine in preclinical experiments, as well as clinical
trials have been reported [4-10]. This approach is basedCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cules by viable recombinant LAB (recLAB) in situ.
The pioneer use of such recLAB for the prevention
and treatment of experimental IBD was performed by
Steidler et al. [11] who developed a recombinant strain
of Lactococcus lactis (the LAB model) secreting biologic-
ally active anti-inflammatory cytokine IL-10. Interest-
ingly, the authors showed that daily oral administration
of L. lactis IL-10 in mice resulted in ~50% reduction in
dextran sulfate sodium (DSS)-induced colitis [11]. The
beneficial effect of L. lactis IL-10 strain was dependent
on the in situ secretion of IL-10 by recombinant live lac-
tococci. Steidler et al. have then developed the first bio-
containment system for L. lactis IL-10 strain to start the
first human clinical study using it [12]. A phase I clinical
trial was then conducted with this biocontained L. lactis
IL-10 strain in Crohn’s disease patients, showing that
the containment strategy was effective [13]. Following
this, a phase IIA trial was performed and a press release
was published in 2009 revealing that all three primary
endpoints have been met: i) safety and tolerability; ii) en-
vironmental containment and iii) assessment of bio-
markers associated with the strain (data from ActoGeniX
press release). Unfortunately, the clinical results did not
reveal a statistically significant difference in mucosal heal-
ing with L. lactis IL-10 versus placebo. In view of these re-
sults, one can wonder whether IL-10 was the right choice
of anti-inflammatory molecule to be delivered by recLAB.
Other anti-inflammatory molecules to be delivered by
recLAB should thus be tested.
Recent work has involved proteases and their endogen-
ous inhibitors in the pathology of IBD [14-16]. Indeed, in-
testinal tissues from CD and UC patients showed elevated
proteolytic activity [14,15]. This high proteolytic activity
could be due to either upregulated protease expression, or
decreased efficacy or expression of endogenous proteases
inhibitors, or both. Transgenic mice producing human
Elafin, an endogenous serine protease inhibitor found in
the human gut, are protected from colitis in various
mouse models of IBD [14]. We thus constructed recom-
binant L. lactis strains able to deliver Elafin at the mucosal
level. We showed that the Elafin delivered by these
recLAB prevents inflammation, accelerates mucosal
healing and restores colon homeostasis in mice [17].
Although Elafin delivery at the mucosal surface by LAB
was shown to efficiently reduce inflammatory signs in
mouse colitis, one can wonder whether other protease
inhibitors with a broader spectrum of inhibition might
be as or more efficient. The Secretory Leukocyte Prote-
ase Inhibitor (SLPI, another serine protease inhibitor)
inhibits the same elastases as Elafin (Elastase and
Proteinase-3), but also inhibits Cathepsin G and tryp-
sin, tryptase and chymase, major proteases contained in
inflammatory cell granules. SLPI therefore appears asanother possible attractive candidate to be delivered by
LAB.
Besides the anti-inflammatory cytokine L. lactis IL-10,
there is also Transforming Growth Factor-β1 (TGF-β)
which is an inhibitory cytokine recognized as a key regu-
lator of immunological homeostasis and inflammatory
responses [18]. Mice deficient for TGF-β1 expression suf-
fered from a more extensive autoimmune process with in-
flammatory infiltrates, involving multiple organs, including
the intestine [19]. More important, despite the broad anti-
inflammatory and immune suppressive actions of TGF-β1,
to our knowledge, the potential anti-inflammatory effects
of a mucosal delivery of this cytokine have not yet been
compared to that of IL-10.
In order to identify the best strategy to treat IBD using
recLAB as mucosal delivery carrier, we thus performed a
comparison between L. lactis strains secreting between cy-
tokines or serine protease inhibitors, using a DSS-induced
colitis mouse model. We compared the efficacy of different
recombinant strains of L. lactis secreting i) either IL-10 or
TGF-β1 as anti-inflammatory cytokines, and ii) either Elafin
or SLPI as serine protease inhibitors. To further identify the
best strategy to use recLAB, we constructed a recLAB
strain inactivated in its major extracellular housekeeping
protease, the high temperature requirement A (HtrA),
which is supposed to produce higher quantities of the de-
sired molecule [20]. Such approach aimed at determining
the best vector, and defined whether a dose-dependent ef-
fect of the delivered molecule is important.
The most efficient protection against colitis was ob-
tained by treatments with Elafin-producing L. lactis strain.
This protective effect was enhanced with the Elafin-
overproducing htrA strain, suggesting a dose-dependent
effect of Elafin delivery. Altogether, these results showed
that serine protease inhibitors are more efficient than
anti-inflammatory cytokines as anti-inflammatory mole-
cules to be delivered by recLAB at the mucosal level for
IBD treatment.
Results
Production of anti-inflammatory cytokines and serine
protease inhibitors by L. lactis
We constructed 4 different recombinant L. lactis strains
that secrete i) either murine IL-10 (LL-IL-10) or mur-
ine TGF-β (LL-TGF-β) as anti-inflammatory cytokines
or ii) either human Elafin (L. lactis Elafin) or murine
SLPI (L. lactis SLPI) as serine protease inhibitors.
Production and secretion of these molecules were eval-
uated, and quantified when possible, by Western blot
and ELISA assays, respectively. As shown in Figure 1A,
a clear band was detected in the supernatant (S) frac-
tion from induced LL-SLPI cultures at the expected size
for mature SLPI (ie. without the SPUsp45); in these
experimental conditions, no signal was detected in the
Figure 1 Characterization of recombinant Lactococcus lactis strains producing either anti-inflammatory molecules (IL-10 and TGF-β1) or
protease inhibitors (Elafin and SLPI). Protein production and secretion were analyzed by Western blotting (panels A, B and C) and ELISA (panel D)
1 h after induction with 1 ng/ml of nisin, the samples were then harvested at late exponential phase (~OD600 = 0.8-1.0). Arrows indicate positions of
mature proteins (eg. mSLPI panel A, human Elafin panel B, and mIL-10 panel C). Abbreviations: C, cell lysates; S, supernatant fraction; M, positions and
sizes of molecular mass markers.
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tion efficiency (~100%). Similar analysis of LL-Elafin
strain resulted in different profiles in C and S samples
(Figure 1B): i) two weak bands in the C fraction which
likely correspond to either anomalous Elafin migration
on SDS-PAGE or Elafin dimers and a weak band which
slightly migrated higher than Elafin and which corre-
sponds to SPUsp45-Elafin precursor (preElafin) and ii) a
clear single band in the S fraction at the expected size
for mature Elafin. In addition, Elafin production andsecretion by recombinant lactococci were quantified by
ELISA and estimated at ~35 ng/ml (Figure 1B).
Concerning IL-10 expression by LL-IL-10, our results
reveal a good production and secretion of this cytokine
by recombinant lactococci since more than 70% was
found in S fraction (Figure 1C). These results were also
validated by ELISA and estimated at 40 ng/ml
(Figure 1C).
TGF-β production by LL-TGF-β strain was assessed
only by ELISA and estimated at 50 ng/ml (Figure 1D).
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ficiently secrete (secretion rate of ~50%) this cytokine.
The quantity of all recombinant molecules secreted
from LAB was more or less in the same order of magni-
tude, insuring thereby the possibility to compare the effi-
ciency of treatments with the different recLAB.
We should mention that none of the recombinant pro-
teins was detected in samples obtained from L. lactis
wild-type (WT) strain used as the negative control for
Western Blot and ELISA assays (Figure 1A-D).
Serine protease inhibitors-expressing L. lactis strains
markedly reduced intestinal inflammation in a
DSS-induced murine colitis model
To define the best strategy to treat IBD using recLAB,
we compared recombinant strains of L. lactis secreting
the different anti-inflammatory candidates, using a DSS-
induced murine colitis model.
Colitis was induced in C57BL/6 mice by addition of
DSS (5% w/v) in drinking water for 7 days. This caused an
acute inflammation characterized by increased macro-
scopic (Figure 2A) and microscopic (Figures 2B and 3)
damage score, increased colon thickness (Figure 2C),
prominent granulocyte infiltration (MPO activity,
Figure 2D) and higher proteolytic activity (Figure 2E
and F) in inflamed colonic tissues. Daily oral adminis-
trations of recombinant L. lactis secreting serine prote-
ase inhibitors resulted in a significant reduction of
inflammation (decreased macroscopic and microscopic
colonic damage scores, colon thickness and MPO activ-
ities), when compared to control mice (treated with ei-
ther PBS or WT L. lactis strain). In addition, lower
elastolytic activity was observed in colonic washes from
mice receiving both LL-Elafin and LL-SLPI (Figure 2E).
Trypsin-like activity was also significantly reduced in
colonic washes from colitic mice that have received oral
treatment with LL-Elafin (Figure 2F). Decreased inflam-
matory signs (damages score, wall thickness and MPO ac-
tivity) were also observed in colonic tissues harvested
from DSS-treated mice treated with L. lactis IL-10
(Figures 2A, B and D and 3). Interestingly, the protective
effects against colitis were higher in mice treated with the
two L. lactis strains recombinant for serine protease inhib-
itors, than those treated with LL-IL-10 (macroscopic and
microscopic score and colon thickness) (Figures 2A and B
and 3).
Recombinant L. lactis strains expressing TGF-
β displayed beneficial effects for MPO activities
(Figure 2D) and histological scores (Figure 2B). How-
ever, this last, was not significantly different when
compared to control mice. These results suggest that
TGF-β is a less efficient anti-inflammatory molecule
when delivered by recombinant L. lactis to treat
colitis.Improving the anti-inflammatory properties of
Elafin-producing L. lactis
As oral administration of serine protease inhibitors-
producing L. lactis strains, and more particularly LL-
Elafin, was the most efficient strategy to inhibit DSS-
induced colitis, we thus evaluated whether an improve-
ment in the Elafin production and secretion by L. lactis
could have an impact on its beneficial effects. We have
previously reported that inactivation of the major L.
lactis housekeeping protease, HtrA, allows high-level
production and secretion of heterologous proteins
[20,21]. We then established pSEC:hElafin plasmid in L.
lactis htrA strain [22] to obtain L. lactis (htrAΔ) Elafin
and assessed Elafin production and secretion by West-
ern blot (Figure 4A). In addition, Elafin secretion by L.
lactis htrAΔ Elafin strain was quantified and compared
with that of its counterpart L. lactis Elafin by ELISA
and estimated at ~55 ng/ml versus 37 ng/ml
(Figure 4A). Since L. lactis htrAΔ strain has tendency
to grow slower than WT L. lactis strain [21] we decided
to compare growth curves (data not shown) of both
strains and to determine elafin production per bacteria
CFU (ng elafin/CFU/time) (Figure 4B). To compare the
amounts of Elafin produced by recombinant L. lactis
the results were normalized to a standard culture vol-
ume of 1 ml of 1.0 OD600 unit of culture (e.g. OD600 =
1 = 5×108 CFU of L. lactis). As shown in Figure 4B,
time-course experiments by ELISA comparing Elafin
production by the two strains revealed that, despite its
lower grow L. lactis htrAΔ strain produces higher levels
of Elafin, compared to its counterpart L. lactis Elafin
strain. This improvement in Elafin yields confirms the
interest of L. lactis htrA strain to enhance production
and secretion of human Elafin. We then compared the
effects of these two strains in the DSS-induced murine
colitis model. As shown in Figure 4C, oral administra-
tion of mice with L. lactis (htrAΔ) Elafin strain resulted
in a better reduction of colonic damage scores, compared
to the L. lactis Elafin strain. Treatment of mice with the L.
lactis htrAΔ Elafin strain was also very efficient to reduce
proteolytic activity in inflamed colonic tissues: both elasto-
lytic (Figure 4D) and trypsin-like activity (Figure 4E). In-
deed, a better inhibition of colonic washes proteolytic
activity was achieved with the L. lactis htrAΔ Elafin strain,
compared to the LL-Elafin strain (Figure 4C-E).
Altogether, these results suggest a dose-dependent effect
of human Elafin when delivered in situ by recombinant L.
lactis.
Methods
Bacterial strains and culture conditions
Escherichia coli TG1 [23] was grown in Luria-Bertani
(Difco) medium at 37°C with vigorous agitation and both
Lactococcus lactis MG1363 [24] and L. lactis NZ9000 [25]
Figure 2 Effects of recombinant lactococci expressing 4 different molecules in a DSS-induced murine colitis model. C57BL/6 mice were given
water or water containing 5% DSS for 7 days and then received daily oral treatments for 7 days with either, vehicle (PBS), L. lactis wild-type (WT), Elafin-,
SLPI-, IL-10- or TGF-β-expressing strains of L. lactis. (A-F). The macroscopic damage (A) and microscopic scores (B), colon wall thickness (C), and MPO activity
(D) in mouse colon tissue are shown. Elastolytic (E) and trypsinolytic (F) activities were assessed in colonic lumenal washes. Significant differences is *,+,#
for p < 0.05 , **,++,## for p < 0.01 ***,+++,### for p < 0.001. + represents significant difference versus DSS and # represents significant difference versus
DSS + L.lactis WT. Data represents cumulative results of 4 independent experiments of n = 6-8 mice per groups.
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(GM17) at 30°C. Antibiotics were used as follows: for E.
coli 100 μg/ml of ampicillin or 15 μg/ml of chlorampheni-
col and for L. lactis 10 μg/ml of chloramphenicol.Construction of recombinant LAB strains
Gene encoding for murine TGF-β1 (mTGF-β1) was amp-
lified by PCR from plasmid pORF9-mTGF-β1 (InvivoGen)
using primers: forward mTGF-β1 (CCAATGCATCAGCC
Figure 3 Representative images of H & E staining on paraffin-wax-embedded sections of the colon of mice are presented. Scale bars
represent 100 μm.
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ACTAGTCCTCAGCTGCACTTG CAGGAGC). Gene
encoding for murine secretory leukocyte protease inhibi-
tor (mSLPI) was amplified by PCR from plasmid pDK6-
mSLPI [26] using primers: forward mSLPI (CCAATG
CATCAGGCAAAAATGATGCTATCAAAATCG) and re-
verse mSLPI (GG ACTAGTCCTCACATCGGGGGCAG
GCAGACTTTCC). PCR products were subcloned into
pCR:TOPO (Invitrogen, Table 1), recovered after digestion
with NsiI/SpeI and cloned into a pSEC backbone purified
from NsiI/NotI-cut pSEC:Nuc [27] (Table 1). Since allprimers were designed to eliminate first genes codons en-
coding for the native signal peptide (SP), in the resulting
plasmids (pSEC:mTGF-β1 and pSEC:mSLPI), genes are
fused in frame with a DNA fragment containing the
ribosome binding site (RBS) and the SP of usp45
(SPUsp45), the gene encoding Usp45, the predominant L.
lactis-secreted protein [28]. In these plasmids, the ex-
pression is controlled by the inducible promoter PnisA,
the activity of which depends upon the concentration
of nisin used [29]. Plasmids were introduced in L. lactis
NZ9000 strain to obtain LL-mTGF-β1 and LL-mSLPI.
Figure 4 Enhancing Elafin production by L. lactis htrA mutant strain, as determined by Western blot (A) and ELISA (B) experiments, led to
higher protective effects in a DSS-induced murine colitis model. C57BL/6 mice (n = 8 in each group) were given water or water containing 5%
DSS for 7 days and then received daily oral treatments for 7 days with either, vehicle (PBS), L. lactis WT, Elafin-expressing L. lactis (L. lactis Elafin) or
Elafin-expressing L. lactis-htra (L. lactis Elafin+). The macroscopic damage score (C) of the colon is shown. Elastolytic (D) and trypsinolytic (E) activities
were assessed in colonic lumenal washes. Significant differences is * for p < 0.05 , ** for p < 0.01 *** for p < 0.001.
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IL-10 (LL-mIL-10) or human Elafine (LL-hElafin) have
been previously reported [17].
Nisin induction, protein samples preparation and
immunoblotting
Recombinant L. lactis strains were grown to an optical
density at 600 nm (OD600) of 0.6, followed by induction
with 1 ng of nisin (SIGMA) per ml for 1 h as previously
described [27]. L. lactis culture extraction and immuno-
blotting assays were performed as follows, using either
murine SLPI (Santa Cruz Biotechnology, Inc., 10538),
human Elafin (Santa Cruz Biotechnology, Inc., sc-20637)
or murine IL-10 (Millipore, AB1492P) polyclonal anti-
bodies. To determine SLPI, Elafin and IL-10 production,
protein samples were prepared from 2 ml of induced
cultures. After centrifugation (5 min, 10,000 g), the cell
pellet (C) and supernatant (S) were treated separately.The S was treated with 100 μl of 100% trichloroacetic
acid (TCA) to precipitate proteins and samples incu-
bated for 10 min on ice. Proteins were recovered in PBS
containing complete protease inhibitor cocktail tablets
(Roche) after centrifugation at 4°C (10 min, 10,000 g).
The C was treated by cell lysis in lysis buffer (25% su-
crose, 1 mM EDTA, 50 mM Tris–HCl pH 8.0 and
10 mg/ml lysozyme) complemented with complete pro-
tease inhibitor cocktail tablets (Roche). Sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis, Western
blotting, and immunodetection were performed following
current protocol. The concentration of Elafin and IL-
10 produced by recombinant lactococci was also
assessed in both C and S samples by enzyme-linked
immuno-absorbent assays: RayBio® human Trappin-2
ELISA Kit (RayBiotech, Inc. ELH-Trappin2-001) for
Elafin and mouse IL-10 ELISA kit HRP (Mabtech,
Sweden, 3431-1H-20).
Table 1 Bacterial strains and plasmids used in this study
Strain or
plasmid




E. coli TG1 supE, hsd, Δ5, thi, Δ(lac-proAB), F’(traD36 proAB-lacZΔM15) [23]
L. lactis MG1363 Wild type strain, plasmid free [24]
L. lactis NZ9000 MG1363 (nisRK genes integrated into chromosome), plasmid free [25]
L. lactis NZ9000 htrA NZ9000 carrying htrA disruption (double-crossover recombination) [22]
Plasmids
pCR-TOPO ApR, subloning TOPO vector Invitrogen
pORF9-mTGF-β1 ApR, pORF9 plasmid carrying murine TGF-β1 gene InvivoGen
pDK6-mSLPI ApR, pDK6 plasmid carrying full length murine secretory leukocyte protease inhibitor (SLPI) cDNA under the
control of the MCMV promoter
[26]
pSEC:Nuc CmR, pGK plasmid (a derivative from the broad host range plasmid pWV01) expressing a secreted form of the
staphylococcal nuclease (Nuc) under the control of PnisA pomoter
[27]
pSEC:mIL-10 CmR, pGK plasmid expressing a secreted form of murine IL-10 cytokine under the control of PnisA promoter [17]
pSEC:elafin CmR, pGK plasmid expressing a secreted form of human elafin antiprotease under the control of PnisA pomoter [17]
pSEC:mTGF-β CmR, pGK plasmid expressing a secreted form of murine TGF-β cytokine under the control of PnisA pomoter This study
pSEC: mSLPI CmR, pGK plasmid expressing a secreted form of murine SLPI antiprotease under the control of PnisA pomoter This study
aFor strains, genotypic and phenotypic characteristics are given; for plasmids, plasmid and cloned-cassette characteristics are given.
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assessed by ELISA as described above using a human/
mouse TGF-β 1 ELISA Ready-SET-Go kit (eBioscience,
88–8350).
Preparation of live bacterial inocula for gavage of animals
RecLAB were grown as described above. Exponential
growth cultures (OD600 = 0.4–0.6) of L. lactis strains
were treated for 1–2 hour with nisin (1 ng/ml; Sigma) to
induce recombinant protein expression. Recombinant
strains of L. lactis were maintained with chlorampheni-
col (10 μg/ml). Bacteria were centrifuged after nisin in-
duction, washed, and resuspended in corresponding
volume of sterile PBS to get a final concentration of
5×109 colony forming units (CFU) for intragastric ad-
ministration (100 μl per mouse).
C57BL/6 mice (6–8 weeks old) were obtained from
Janvier (Le Genest Saint Isle, France). All mice were kept
at room temperature under 12 h light/dark cycles, and
had free access to food and water. All procedures were
approved by the Animal Care Committee “Midi-Pyrén-
ées” (MP/06/12/02/12).
Induction of colitis and study design
Colonic inflammation was induced by treatment with
DSS (MP Biomedicals, Illkirch, France 160110), dis-
solved in drinking water (5% weight/volume). The ani-
mals were free to drink the DSS solution for 7 days. For
the whole period of DSS exposure, mice were dailytreated by intragastric gavage with 5×109 CFU (in
100 μL PBS) of either wild-type (WT) or recombinant L.
lactis strains or PBS (100 μL). Body weight was mea-
sured daily after the induction of colitis. On day 7 after
adding DSS to their drinking water, mice were sacrificed
and colons were analyzed and harvested for measure-
ment of inflammation parameters: macroscopic and
microscopic damage score, bowel thickness, myeloper-
oxydase (MPO) activity as previously described
[14,17]. Upon sacrifice, the entire colon was excised
and 1 ml PBS was instilled and washed twice through
the lumen. Trypsin-like and elastase/PR-3-like activities
were measured in those washes, using tosyl-Gly-Pro-
Arg-p-nitroanilide (150 μM, Sigma) and MeO-succinyl-
Ala-Ala-Pro-Val- p-nitroanilide (100 μM, Sigma)
respectively as substrates. The change in absorbance at
405 nm was determined over 30-minutes at 37°C with a
microplate reader NOVOstarTM (BMG Labtech,
Champigny-sur-Marne, France). Activity was compared
to known standard dilution of trypsin from porcine
pancreas (Sigma) or human NE (Sigma) [14,17].Statistics
Data are presented as mean bars graph ± SEM. Statistical
analysis were performed using one-way analysis of vari-
ance (ANOVA), followed by suitable post hoc compari-
son tests (Bonferroni’s or Dunnett’s). A P value less than
0.05 was considered significant. Graphic design and
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Prism software version 5 for Windows.
Discussion
The treatment of IBD represents one of the major chal-
lenges of modern medicine as they concern several mil-
lions of people. Current therapies for IBD strongly need
to be improved since a high percentage of patients (20–
40%) are resistant to any forms of treatments [30].
Moreover, severe side-effects and high costs are fre-
quently associated to the currently available drugs (e.g.
glucocorticoids and monoclonal antibody therapies).
Over the past 10 years, there has been increasing
interest in the use of LAB as oral delivery vectors [4,7].
More particularly, the use of recombinant L. lactis se-
creting IL-10 for the prevention and treatment of colitis
in different mouse models has been largely studied [11].
To date, two human clinical trials have been carried out
with a biologically contained-derivative LAB (ie. lactic
acid bacteria) secreting IL-10 [12]. The first study was
performed in the Netherlands and assessed LAB IL-10
effects in Crohn’s disease patients. The results of this
small phase I human trial, showed positive effects con-
cerning biological containment, safety and tolerability
[13]. In the second study (a phase IIa human clinical
trial), ActoGenix (a company which develops genetically
modified L. lactis for mucosal delivery of therapeutic
molecules), assessed the effects of LAB IL-10 in subjects
with moderately active ulcerative colitis. Unfortunately,
although the results confirmed the suitability of the ap-
plied containment system in humans, no significant clin-
ical effects were observed in this study (ActoGenix press
release published at the end of 2009). This limited effi-
cacy could be explained either by the fact that IL-10 is
not the best molecule of choice to be used in a recLAB
system, or by the fact that the IL-10 quantities delivered
were not sufficient to be efficient in the intestinal
environment.
The choice of IL-10 as a molecule to be delivered by
LAB is supported by the anti-inflammatory effects of
this cytokine [31]. As a matter of fact, mice deficient for
IL-10 develop spontaneous colitis [32]. However, while
systemic treatments with recombinant IL-10 are safe
and well tolerated, they have a low therapeutic efficacy
compared with placebo [33]. This suggests that pharma-
codynamics of IL-10 are subtle and potentially needs a
sustained and more mucosa-focused delivery to be effi-
cient against colitis. Indeed, sustained delivery of IL-10
through adenovirus-based strategy showed better results
in animal models [34,35], whether the colitis was in-
duced by IL-10 deficiency or by chemicals. However, dis-
crepancy exists on the fact that adenovirus-based IL-10
systemic delivery might not be able to reduce established
colitis [36]. Local delivery of IL-10, through intracolonicadministration of an adenovirus expressing IL-10 was
able to reduce colitis in IL-10-deficient mice [37]. How-
ever, no study has investigated whether this mucosal de-
livery of IL-10 was efficient against colitis involving
other mediators than only IL-10 deficiency. This ap-
proach of using LAB as vectors for IL-10 mucosal deliv-
ery [11], ensure a sustained and local (mucosal surface)
delivery. However, IL-10 is released within the lumen,
and might not be able to penetrate deep into the tissues
and to exert its anti-inflammatory properties within mu-
cosal tissues. IL-10 has broad immunoregulatory activity,
acting to suppress intestinal inflammation on several
levels. It inhibits TH1 lymphocyte differentiation; it di-
minishes antigen presentation and IL-12 release, and
promotes differentiation and activity of regulatory T cells
[31,38]. All these activities are related to actions on im-
mune cells present in the lamina propria, not at the mu-
cosal surface. Taken together, all these facts argue
against considering IL-10 as a molecule of choice to be
delivered by recLAB, and indeed, we demonstrated that
treatments of colitic mice with IL-10 recLAB was not ef-
ficient on most parameters of intestinal inflammation.
We cannot discard also that the minor effect observed
with the LL-IL-10 strain was due to our murine colitis
model. Indeed, acute colitis models induced by DSS are
characterized by massive epithelial damage and it has
been well established that IL-10 gave the best results in
chronic colitis models that are immunological driven.
TGF-β1, another anti-inflammatory cytokine that
could recapitulate some of the effects of IL-10 on im-
mune cells, but that could also exert protective effects
on intestinal epithelial cells, at the mucosal surface, ap-
peared as a better candidate to be delivered by recLAB.
Like IL-10, TGF-β1 exerts multiple actions on immune
cells (regulatory T cells, Th17 cells, monocytes, macro-
phages) and is also protective in intestinal epithelial
cells. Beck et al. have shown that TGF-β1 is required for
intestinal mucosal healing, and strongly decreases the
epithelial susceptibility to injury [39]. TGF-β1 also in-
hibits intestinal barrier disruption, by a direct effect on
intestinal epithelial cells [40,41]. Thus, we constructed
TGF-β1 recombinant L. lactis strain and tested this
treatment against DSS-induced colitis. Like for IL-10 re-
combinant LAB, LL-TGF-β oral treatments were poorly
effective against colitis. Such treatment only reduced
granulocytes infiltration (Figure 2D), but not the other
parameters of inflammation. Here again, one can wonder
if TGF-β1 is the molecule of choice to be delivered by
LAB, and could exert its anti-inflammatory effects, once
released in the lumen. Therefore, we tested the effects of
a completely different family of anti-inflammatory mole-
cules, which are released by the intestinal epithelium,
and at the mucosal surface: the serine protease inhibi-
tors. Both Elafin and SLPI, when delivered by L. lactis
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induced colitis and were as effective (Figure 2). These
serine protease inhibitors have different spectra of inhib-
ition, SLPI being able to inhibit Cathepsin G and a num-
ber of trypsin like proteases (trypsin, tryptase and
chymase), in addition to Elastase and Proteinase-3, also
inhibited by Elafin [42,43]. This suggests that the sole in-
hibition of Elastase and Proteinase-3 is sufficient to ob-
tain strong anti-inflammatory effects. Cathepsin G and
trypsin-like inhibition should not provide additional pro-
tective effects. Treatments with recombinant L. lactis
strains delivering either SLPI or Elafin were both more
efficient to reduce signs of colitis, than treatments with
anti-inflammatory cytokines recLAB. Endogenous prote-
ase inhibitors released physiologically by the intestinal
epithelium thus appear as better molecules to be deliv-
ered by L. lactis, to generate potent therapeutic option.
Indeed, these two protease inhibitors are pleiotropic in
their role as guardian of mucosal surfaces. They not only
inhibit the effects of proteases released by inflammatory
cells, but they also inhibit pro-inflammatory transcrip-
tion factors (AP-1, NF-κB), restore barrier functions, and
exert antimicrobial activity [17,26,43,44]. Released by
LAB in the lumen, Elafin and SLPI can potentially exert
their anti-inflammatory biological functions more easily
than anti-inflammatory cytokines. In addition, Elafin and
SLPI might impact on the microbiota composition, due
to their antimicrobial activity, might not be negligible.
Such role could add to the protective effects they might
have on the host [43].
An important point to consider when using the recLAB
technology is the quantity of protein of interest that is de-
livered at the mucosal surface. Here, we showed that treat-
ment with L. lactis strain inactivated in the main
extracellular protease and thus able to release more pro-
tein of interest (Elafin), is more efficient at reducing colitis.
Therefore, the recLAB technology could be improved by
using such L. lactis mutant. The quantity of protein re-
leased at the mucosal surface could also depend on the
time the bacteria will survive in the gastrointestinal tract
(GIT). One of the hypotheses for the lack of effect of treat-
ment with L. lactis IL-10 in clinical trials, was the fact that
this bacterium has a weak resistance to the gastrointestinal
environment [45]. Although our experiments were per-
formed in mice and not in human like the clinical trials,
we have observed that even with L. lactis as a vector,
serine protease inhibitors were more potent anti-
inflammatory molecules than IL-10 or TGF-β1. Nonethe-
less, other LAB vectors more persistent in the GIT (as
lactobacilli) to deliver the proteins of interest should be
tested to improve the kinetics and associated quantity of
protein delivered at mucosal surfaces.
In conclusion, we have observed that the use of L. lac-
tis strains expressing anti-proteases (Elafin or SLPI) ismore efficient than the use of either LL-IL-10 or LL-
TGF-β in this colitis model, to decrease intestinal in-
flammation. This differential effect could be explained
by the different anti-inflammatory functions of these
classes of molecules, and the fact that L. lactis vector de-
livery might be more appropriate with mucosal surface
proteins such as protease inhibitors, than proteins exert-
ing most of their effects in the lamina propria, such as
anti-inflammatory cytokines. These results strongly sug-
gest that the administration of recombinant L. lactis
strains expressing serine protease inhibitors would raise
more interest than the L. lactis IL-10 recombinant ap-
proach for IBD treatment.
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